Biowaiver: An alternative to in vivo pharmacokinetic bioequivalence studies

Pharmazie

Volumn 65, Issue 3, 2010, Pages 155-161

  Mishra, V ^a   Gupta, U ^a   Jain, Narendra K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ACICLOVIR; AMOXICILLIN; ATENOLOL; ATOVAQUONE; CAFFEINE; CARBAMAZEPINE; CHLOROTHIAZIDE; CIMETIDINE; DANAZOL; FUROSEMIDE; GLIBENCLAMIDE; GRISEOFULVIN; KETOCONAZOLE; KETOPROFEN; LABETALOL; MACROGOL 400; MANNITOL; METOPROLOL; NADOLOL; NAPROXEN; PARACETAMOL; PHENAZONE; RANITIDINE; SOTALOL; THEOPHYLLINE; TIMOLOL; TROGLITAZONE; UNINDEXED DRUG; VERAPAMIL;

BIOEQUIVALENCE; COST CONTROL; DRUG ABSORPTION; DRUG DESIGN; DRUG ELIMINATION; DRUG PENETRATION; DRUG SOLUBILITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TRACT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUTH CAVITY; NONHUMAN; PERFORMANCE; PREDICTION; REVIEW; SIMULATION; STANDARD; TIME;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; HUMANS; INTESTINAL ABSORPTION; MOUTH; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY; THERAPEUTIC EQUIVALENCY;

EID: 77949419950     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.9231     Document Type: Review

References (38)

1. Amidon GL, Lennernas H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12: 413-420.
2. Artursson P (1990) Epithelial transport of drugs in cell culture: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci 79: 476-482.
3. Artursson P, Karlsson J (1991) Correlation between oral drug absorption in human and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175: 880-885.
4. Blume HH, Schug BS (1999) The biopharmaceutics classification system (BCS): class III drugs-better candidate for BA/BE waiver? Eur J Pharm Sci 9: 117-121.
5. Cheng CL, Yu LX, Lee HL, Yang CY, Lue CS, Chou CH (2004) Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur J Pharm Sci 22: 297-304.
6. Dimond PF (2005) Using nanotechnologies in biotech and medicine. Gen Eng News 25: 21.
7. Dressman BJ, Reppas C (2000) In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 11: 73-80.
8. Dressman J, Butler J, Hempenstall J, Reppas C (2001) The BCS: Where Do We Go from Here? Pharm Tech 68-76.
9. Dressman JB, Amidon GL, Reppas C, Shah VP (1998) Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 15: 11-22.
10. FDA Guidance (2000b) The Biopharmaceutics Classification System (BCS). Food and Drug Administration, Rockville, MD.
11. FDA Guidance for Industry (1997a) Dissolution testing for immediate release solid oral dosage forms. Food and Drug Administration, Rockville, MD.
12. FDA Guidance for Industry (1997b) Extended release oral dosage forms: development, evaluation and application of an in vitro/in vivo correlation. Food and Drug Administration, Rockville, MD.
13. FDA Guidance for Industry (2000a) Bioavailability and bioequivalence studies for orally administered drug products-general considerations. Food and Drug Administration, Rockville, MD.
14. FDA Guidance for Industry (2000c) Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Food and Drug Administration, Rockville, MD.
15. Fleisher D, Li C, Zhou Y, Pao LH, Karim A (1999) Drug, meal and formulation interactions influencing drug absorption after oral administration: Clinical implications. Clin Pharmacokinet 36: 233-254.
16. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadee W, Amidon GL (1998) 5γ-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res 15: 1154-1159.
17. Hidalgo I, Raub T, Borchardt R (1989) Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96: 736-49.
18. Hilgers AR, Conradi RA, Burton PS (1990) Caco-2 monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 7: 902-910.
19. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennern̈as H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL (2004) Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1: 85-96.
20. Kortejarvi H, Urtti A, Yliperttula M (2007) Pharmacokinetic simulation of biowaiver criteria: The effects of gastric emptying, dissolution, absorption and elimination rates. Eur J Pharm Sci 30: 155-166.
21. Lennernäs H (1998) Human Intestinal Permeability: An Overview. J Pharm Sci 87: 403-410.
22. Lennernäs H, Abrahamsson B (2005) The use of the Biopharmaceutic Classification in drug discovery and development: current status and future extension in drug bioavailability, estimation of solubility, permeability, absorption and bioavailability. J Pharm Pharmacol 57: 273-285.
23. Lennernas H, Lee ID, Fagerholm U, Amidon GL (1997) A residence-time distribution analysis of the hydrodynamics within the intestine in man during a regional single-pass perfusion with Loc-I- Gut: in-vivo permeability estimation. J Pharm Pharmacol 49: 682-686.
24. Pelkonen O, Boobis AR, Gundert-Remy U (2001) In vitro prediction of gastrointestinal absorption and bioavailability: an experts' meeting report. Eur J Clin Pharmacol 57: 621-629.
25. Polli JE, Yu LX, Cook JA, Amidon GL, Borchardt RT, Burnside BA, Burton PS, Chen, ML, Conner DP, Faustino PJ, Hawi AA, Hussain AS, Joshi HN, Kwei G, Lee VH, Lesko LJ, Lipper RA, Loper AE, Nerurkar SG, Polli JW, Sanvordeker DR, Taneja R, Uppoor RS, Vattikonda CS,Wilding I, Zhang G (2004) Summary workshop report: Biopharmaceutics Classification System-implementation challenges and extension opportunities. J Pharm Sci 93: 1375-1381.
26. Rinaki E, Dokoumetzidis A, Valsami G, Macheras P (2004) Identification of biowaivers among class II drugs: theoretical justification and practical examples. Pharm Res 21: 1567-1572.
27. Sun D,Yu LX, Hussain MA,Wall DA, Smith RL, Amidon GL(2004) In vitro testing of drug absorption for drug developability assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr Opin Drug Discovery Dev 7: 75-85.
28. Tamura S, Tokunaga Y, Ibuki R, Amidon GL, Sezaki H, Yamashita S (2003) The site-specific transport and metabolism of tacrolimus in rat small intestine. J Pharm Exp Ther 306: 310-316.
29. Uppoor VRS (2001) Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Contrl Rel 72: 127-132.
30. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Möller H, Olling M, Shah VP, Barends DM (2004) Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci 93: 1945-1956.
31. Walter E, Janich S, Roessler BJ, Hilfinger JM, Amidon GL (1996) HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci 85: 1070-1076.
32. Wilson G, Hassan IF, Dix CJ, Williamson I, Shah R, Mackay M (1990) Transport and permeability properties of human Caco-2 cells: An in vitro model of the intestinal epithelial cell barrier. J Controlled Rel 11: 25-40.
33. Wu CY, Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22: 11-23.
34. Yang Y, Faustino PJ, Volpe DA, Ellison CD, Lyon RC, Yu LX (2007) Biopharmaceutics Classification of Selected β-Blockers: Solubility and Permeability Class Membership. Mol Pharma 4: 608-614.
35. Yee S (1997) In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res 14: 763-766.
36. Yu LX (1999) An integrated absorption model for determining causes of poor oral drug absorption. Pharm Res 16: 1883-1887.
37. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, Hussain AS (2002) Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 19: 921-925.
38. Yu LX, Carlin AS, Amidon GL, Hussain AS (2004) Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int J Pharm 270: 221-227.